Get the Stockscreener App
28.61
1.15%
-0.40
Rigel Pharmaceuticals stock is traded at $28.61, with a volume of 113.19K.
It is down -1.15% in the last 24 hours and down -5.33% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
See More
Previous Close:
$29.01
Open:
$29.17
24h Volume:
113.19K
Relative Volume:
0.29
Market Cap:
$530.18M
Revenue:
$294.28M
Net Income/Loss:
$367.02M
P/E Ratio:
1.5128
EPS:
18.9115
Net Cash Flow:
$75.66M
1W Performance:
+1.33%
1M Performance:
-5.33%
6M Performance:
-43.73%
1Y Performance:
+51.32%
1-Day Range:
$28.63
$29.34
1-Week Range:
$27.88
$29.70
52-Week Range:
$18.14
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
28.66 | 536.75M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
436.96 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.05 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.41 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.00 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.91 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
RIGL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $57 - GuruFocus
RIGL Stock Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals Presents GAVRETO Phase 3 Data at ASCO 2026 - Intellectia AI
META_TITLE_QUOTE - Yahoo Finance
Rigel cancer drugs post multi-year responses in lung and relapsed leukemia - Stock Titan
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? - MSN
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) M&A CallSlideshow (NASDAQ:RIGL) 2026-05-20 - Seeking Alpha
Rigel Shareholders Approve Equity Plans and Board Slate - TipRanks
Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting - Stock Titan
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs - TipRanks
Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead - simplywall.st
RIGEL (RIGL) director Kamil Ali-Jackson receives 5,750-share RSU board grant - Stock Titan
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug - MSN
Rigel Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Q3 2025 Earnings Preview - MSN
Avoiding Lag: Real-Time Signals in (RIGL) Movement - Stock Traders Daily
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU - simplywall.st
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
Armistice Capital (RIGL) reports 1.28M shares, 6.93% stake - Stock Titan
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - RTTNews
Rigel Pharmaceuticals inks worldwide agreement to develop and commercialize VEPPANU - Traders Union
Rigel Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference - Moomoo
These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Sahm
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
RIGL Maintained by Citigroup -- Price Target Raised to $81.00 - GuruFocus
Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu | PharmExec - PharmExec.com
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu - PharmExec.com
New Haven biotech Arvinas signs potential $405M drug licensing deal - Hartford Business Journal
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $81 - Moomoo
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $81 - Moomoo
Rigel snaps up breast cancer drug Veppanu in up to $405m deal - The Pharma Letter
Rigel Pharmaceuticals Enters License Agreement for VEPPANU™ with Arvinas and Pfizer – 8-K Filing Details - Minichart
Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story - simplywall.st
[8-K] RIGEL PHARMACEUTICALS INC Reports Material Event - Stock Titan
Rigel Pharmaceuticals inks deal with Arvinas and Pfizer for breast cancer drug VEPPANU, shares jump 10.7%. - Pluang
Pfizer (PFE) Enters Licensing Deal with Rigel Pharmaceuticals - GuruFocus
Rigel Pharmaceuticals stock rises on Veppanu licensing deal - Investing.com
Why Is Rigel PharmaceuticalsArvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE), Rigel Pharmaceuticals (NASDAQ:RI - Benzinga
Arvinas, Pfizer, and Rigel Partner on Veppanu (Vepdegestrant) Breast Cancer Drug - geneonline.com
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu - TipRanks
Biopharma bites: Rigel buys beleaguered PROTAC, Bayer's pipeline trim, and more from Novo Nordisk, Delos Capital - FirstWord Pharma
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? - Stocktwits
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug - BioPharma Dive
Coming through on Veppanu with back-loaded Rigel deal - BioWorld News
Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu - Fierce Pharma
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOOS WALTER H | Director |
Feb 20 '26 |
Option Exercise |
24.00 |
4,000 |
96,000 |
16,722 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Sale |
36.36 |
4,000 |
145,440 |
12,722 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):